JPA Health | O'Dwyer's PR Firms Directory
Premier database and directory of PR firms & public relations agencies. Find the firm that best suits your needs.
Source: odwyerpr.com
Lisa Rivero News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lisa Rivero. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lisa Rivero Today - Breaking & Trending Today
MULTIMEDIA UPDATE - Albireo Announces FDA Approval of
– Commercial launch of Bylvay immediate; available for prescription in the coming days – – Rare Pediatric Disease Priority Review Voucher issued to Albireo by the FDA – – Company to host investor conference call on July 21 at 8:30 a.m. ET – BOSTON, July 20, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced U.S. Food & Drug Administration (FDA) approval of Bylvay (odevixibat), the first drug approved for the treatment of pruritus in all subtypes of progressive familial intrahepatic ...
Source: globenewswire.com
New Phase 3 Data at WCPGHAN Show Long-Term Safety, Tolerability, and Treatment Benefits of Bylvay™ (odevixibat) in PFIC
– Data being presented show long-term benefits of Bylvay in children with PFIC – – First potential non-invasive treatment option that could transform the ...
Source: benzinga.com
Local press expands its reach by publishing novel 'Bone Broth'
Local Hidden Timber Books looks to grow audience by publishing 'Bone Broth,' powerful novel about Black activists
Source: jsonline.com
Albireo Pharma, Inc.: Albireo Receives Positive CHMP Opinion for Bylvay (odevixibat) for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)
- Bylvay has the potential to become first approved drug to treat all forms of PFIC - - CHMP opinion is based on the PEDFIC Phase 3 studies - - PEDFIC 1 met the bile acid (P=0.003) and pruritus
Source: finanznachrichten.de